Prasugrel approved by the FDA

Revision as of 20:49, 10 July 2009 by C Michael Gibson (talk | contribs) (New page: July 10 by C. Michael Gibson, M.S., M.D. (click here for Dr. Gibson's disclosures) The Food and Drug Administration announced today that Prasugrel (which will ...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


July 10 by C. Michael Gibson, M.S., M.D. (click here for Dr. Gibson's disclosures)

The Food and Drug Administration announced today that Prasugrel (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding.

It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg.

The drug is marketed by both Eli Lilly and Daiichi-Sankyo.

Retrieved from "https://www.wikidoc.org/index.php?title=Prasugrel_approved_by_the_FDA&oldid=553153"